1-9 of 9
Feng Zhao
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers

Patricia J. Keller, Elizabeth J. Adams, Rentian Wu, Alexandre Côté, Shilpi Arora, Nico Cantone, Rosana Meyer, Jennifer A. Mertz, Victor Gehling, Jike Cui, Jacob I. Stuckey, Avinash Khanna, Feng Zhao, Zehua Chen, Ziyang Yu, Richard T. Cummings, Mohammed Taimi, Nehal J. Lakhani, Drew Rasco, Martin Gutierrez, Linda Duska, Michael Devitt, Ronda Rippley, Julian Levell, Jennifer Truong, Jing Wang, Kaiming Sun, Patrick Trojer
Journal: Cancer Research
Cancer Res (2024) 84 (15): 2501–2517.
https://doi.org/10.1158/0008-5472.CAN-24-0398
Published: 01 August 2024
View article titled, Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <em>ARID1A</em> Mutant Cancers
Open the PDF for Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <em>ARID1A</em> Mutant Cancers in another window
Includes: Supplementary data
Journal Articles

Abstract 2126: Therapeutic potential of CPI-0209

Rentian Wu, Feng Zhao, Patricia J. Keller, Jennifer A. Mertz, John P. McGrath, Barbara Bryant, Andrew R. Conery, Kaiming Sun, Jing Wang, Patrick Trojer
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 2126.
https://doi.org/10.1158/1538-7445.AM2021-2126
Published: 01 July 2021
View article titled, Abstract 2126: Therapeutic potential of CPI-0209
Journal Articles

Abstract B31: EZH2 suppresses the interferon-stimulated gene response in non-Hodgkin lymphoma

William D. Bradley, Chih-Chi Yuan, Feng Zhao, Christina Lee, Kaylyn E. Williamson, Shilpi Arora, Charlie Hatton, Barbara M. Bryant, Patrick Trojer
Journal: Cancer Research
Cancer Res (2016) 76 (2_Supplement): B31.
https://doi.org/10.1158/1538-7445.CHROMEPI15-B31
Published: 14 January 2016
View article titled, Abstract B31: EZH2 suppresses the interferon-stimulated gene response in non-Hodgkin lymphoma
Journal Articles

Abstract 5526: Inhibition of the histone methyl transferase EZH2 causes viability defects in multiple myeloma

Shilpi Arora, Vidya Balasubramanian, Kaylyn Williamson, Victor Gehling, Chris Nasveschuk, Rishi Vaswani, Jennifer Busby, Shivani Garapaty, Priya Iyer, Feng Zhao, Robert Campbell, Richard Cummings, Jim Audia, JC Harmange, Brian Albrecht, Andrew Cook, Les Dakin, Emmanuel Normant, Patrick Trojer
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 5526.
https://doi.org/10.1158/1538-7445.AM2014-5526
Published: 01 October 2014
View article titled, Abstract 5526: Inhibition of the histone methyl transferase EZH2 causes viability defects in multiple myeloma
Journal Articles

Abstract 2426: Role of fibroblast growth factor receptor 1 (FGFR1) in liver metastasis of colorectal cancer

Myung Eun Lee, Yoo Kun Shin, Hei-Cheul Jeung, Sang Joon Shin, Young Kyu Park, Xue-Feng Zhao, Tae Soo Kim, Joong- Bae Ahn, Hyun Cheol Chung, Sun Young Rha
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 2426.
https://doi.org/10.1158/1538-7445.AM2012-2426
Published: 15 April 2012
View article titled, Abstract 2426: Role of fibroblast growth factor receptor 1 (FGFR1) in liver metastasis of colorectal cancer
Journal Articles

Abstract 1222: Down-regulation of MEIS2 leads to apoptosis in human colorectal cancer cells

Chang Soo Hong, Xue-Feng Zhao, Sung Min Moon, Hye Won Lee, Snag Rok Lee, Yong Kyu Park
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 1222.
https://doi.org/10.1158/1538-7445.AM10-1222
Published: 15 April 2010
View article titled, Abstract 1222: Down-regulation of MEIS2 leads to apoptosis in human colorectal cancer cells
Journal Articles

Abstract 1032: Impact of HOXC9 recapitulation on cancer biology and clinical outcome in gastric cancer

Sungmin Moon, Changsoo Hong, Sangrok Lee, Xue-Feng Zhao, Hyewon Lee, Semi Kim, Sang-Uk Han, Ik-Joo Chung, Young-Kyu Park
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 1032.
https://doi.org/10.1158/1538-7445.AM10-1032
Published: 15 April 2010
View article titled, Abstract 1032: Impact of HOXC9 recapitulation on cancer biology and clinical outcome in gastric cancer
Journal Articles

IPI-504, a novel HSP90 inhibitor is effective in EGFR T790M and non-T790M gefitinib-resistant lung cancer cell lines.

Joon Park, Feng Zhao, Kreshnik Zejnullahu, Kelly Slocum, Emmanuel Normant, Jeffrey Engelman, Bruce Johnson, Pasi Janne
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 2450.
Published: 01 May 2008
View article titled, IPI-504, a novel HSP90 inhibitor is effective in <em>EGFR</em> T790M and non-T790M gefitinib-resistant lung cancer cell lines.
Journal Articles

PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib

Jeffrey A. Engelman, Kreshnik Zejnullahu, Christopher-Michael Gale, Eugene Lifshits, Andrea J. Gonzales, Takeshi Shimamura, Feng Zhao, Patrick W. Vincent, George N. Naumov, James E. Bradner, Irene W. Althaus, Leena Gandhi, Geoffrey I. Shapiro, James M. Nelson, John V. Heymach, Matthew Meyerson, Kwok-Kin Wong, Pasi A. Jänne
Journal: Cancer Research
Cancer Res (2007) 67 (24): 11924–11932.
https://doi.org/10.1158/0008-5472.CAN-07-1885
Published: 18 December 2007
View article titled, PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with <em>EGFR</em> and <em>ERBB2</em> Mutations that Are Resistant to Gefitinib
Open the PDF for PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with <em>EGFR</em> and <em>ERBB2</em> Mutations that Are Resistant to Gefitinib in another window
Includes: Supplementary data